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ABSTRACT 
 In July, the U.S. Department of Health and Human Services (HHS), in association with 
the Office of Human Research Protections (OHRP) and the Food and Drug Administration 
(FDA), issued an Advance Notice of Proposed Rulemaking focused on modernizing the federal 
regulations for the protection of human subjects.  Three areas targeted for revisions would have a 
substantial effect on how IRBs review human subjects research: ensuring risk-based protections, 
streamlining IRB review of multi-site studies and improving informed consent.  The current 
study aimed to assess IRB Directors‟ perceptions of these proposed revisions and identify any 
barriers to implementation.  The results of the study showed that IRB Directors agree that the 
federal regulations need to be updated and generally agree with the proposed revisions regarding 
mandating singe IRB review of multi-site studies and efforts to improve the length and 
complexity of informed consent forms.  However, subjects did not agree with the proposed 
changes in regards to the new “excused” category, specifically the concept of allowing 
investigators to register studies with the IRB opposed to submitting for IRB review and approval 
prior to commencing research activities. 
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INTRODUCTION 
 In a July 22, 2011 news release, the U.S. Department of Health and Human Services 
(HHS), in association with the Office of Human Research Protections (OHRP) and the Food and 
Drug Administration (FDA), announced their intent to introduce a “proposal to improve rules 
protecting human research subjects.”
1
  The proposal, titled “Human Subjects Research 
Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators,” was published in the July 26, 2011 Federal Register as an Advance 
Notice of Proposed Rulemaking (ANPRM).
2
   
The purpose of the ANPRM was to solicit comments from the public on various 
enhancements and revisions that HHS was considering to the Code of Federal Regulations.  
Regulations pertaining to the protection of human subjects are listed in both Subpart A 45 CFR 
part 46
3
 (regularly referred to as the “Common Rule”) for all federally funded human subjects 
research, and 21 CFR parts 50, 56, 312 and 812
4
 for research regulated by the FDA. 
   Acknowledging that the regulations have not “kept pace with the evolving human 
research enterprise, the proliferation of multi-site clinical trials and observational studies, the 
expansion of health services research, research in social and behavioral sciences, and research 
involving databases, the Internet, and biological specimen repositories, and the use of advanced 
technologies, such as genomics” (p. 44512), HHS proposes to modernize the regulations which 
have not been significantly revised since their adoption in 1991.
2
   In the ANPRM, HHS targets 
seven areas for enhancement that have been criticized over the years: 
I. Ensuring risk-based protections 
II. Streamlining Institutional Review Board (IRB) review of multi-site studies 
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III. Improving informed consent 
IV. Strengthening data protections to minimize informational risks 
V. Data collection to enhance system oversight 
VI. Extension of federal regulations 
VII. Clarifying and harmonizing regulatory requirements and agency guidance 
As evident by the title of the proposal, HHS‟s intentions are to enhance protections of 
human subjects and reduce regulatory burdens that are adversely affecting investigators and 
delaying the progress of valuable research.  However, the realization of any enhancements in 
protections and reductions of regulatory burden will be determined by how effectively IRBs 
interpret and apply the final revisions.  In most academic institutions, the interpretation of the 
final revisions and their subsequent translation into effective enhancements will be the 
responsibility of the directors of the administrative support offices for the IRB.  
Focusing on the three targeted areas for revision which will have the greatest effect on 
how IRBs categorize, review and approve human subjects research studies (ensuring risk-based 
protections, streaming IRB review multi-site studies, and improving informed consent), the 
objective of the current research study is to: 
I. Assess how IRB directors perceive the regulatory changes as proposed by HHS, and  
II. Identify any potential concerns about or barriers to implementation of the revisions as 
proposed. 
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BACKGROUND 
Commonly characterized as bureaucratic in nature, many investigators believe that IRBs 
have become overregulated and inefficient.
5,6,7,8,9
  Contributing to this criticism is the fact that 
IRB effectiveness has historically been measured by administrative benchmarking opposed to the 
examination of the substance of IRB review and ethical issues at stake.
6,10
  As Hyman (2007) 
noted: 
The use of forms as the locus for decision-making resulted in a check-the-box mentality 
among IRB personnel, where the substantive content of research was less important than 
the forms that had been submitted...  These tendencies are worsened by the fact that 
evaluation of IRB performance is based on whether all forms and paperwork were filled 
out correctly, and whether IRB decisions were properly documented. 
6
 (p. 762) 
The reality is that local IRBs are tasked with complying with best practices and standards 
set and enforced by the federal agencies and accreditation bodies.  In addition, the ever-evolving 
research enterprise has introduced challenges in the form of increased workloads and difficulty 
recruiting new IRB members with valued expertise to volunteer their services.  While some 
individual IRBs have tried implementing revised meeting schedules, increasing membership 
numbers to facilitate the rotation of members according to expertise and even paying members 
for their service to attempt to gain efficiencies and reduce delays,
11
 the resources to implement 
these changes are not available to every IRB.  The impetus of the sweeping reform called for by 
the research community must come from the federal agencies and accreditation bodies 
themselves.  Until then IRBs, and the administrations they report to, will be afraid to redirect 
focus and deviate from accepted standards for fear of punitive actions.  
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The proposed revisions outlined in the ANPRM aim to provide the regulatory relief 
necessary to allow IRBs to more efficiently review human subjects research while maintaining 
meaningful protections.  Specifically, the suggested changes in regard to ensuring risk-based 
protections, streamlining IRB review of multi-site studies and improving informed consent have 
the potential to allow IRBs to shift resources away from time-consuming activities and 
procedures that don‟t contribute significant protections.    
Ensuring Risk-Based Protections 
 Wendler & Varma (2006) analyzed nine studies submitted to the Secretary of HHS under 
45 CFR 46.407, a section of the regulations which allows IRBs to forward pediatric research 
studies to the Secretary that the IRB believes pose greater than minimal risk of harm to subjects 
without any prospects of direct benefit to the subjects.  The investigators found that the research 
interventions in 8 of the 9 studies submitted to the Secretary for review actually did not pose 
risks greater than the level of risks that children encounter in daily life or during the performance 
of routine physical or psychological tests.
9
  These findings illustrate one of the criticisms of the 
current regulations: that the level of scrutiny by IRBs does not always correlate with the level of 
possible risk proposed by the research. 
 To address this issue, HHS proposes several revisions to the Common Rule “intended to 
ensure that protections are commensurate with the level of risk of the research study”
2
 (p. 
44515).  Though the proposed revisions do address the issue raised by Wendler & Varma (2006) 
by including more specific language to help IRBs make determinations of minimal risk, it is 
possible that other proposed changes will actually have a greater impact on IRB efficiency and/or 
function.  Several of these proposed changes can assumedly result in tangible changes to the 
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review requirements for minimal risk studies which could translate into reduced IRB oversight.  
HHS hopes that by lessening some of the scrutiny on studies which do not pose greater than 
minimal risk, IRB resources can be re-directed to enhancing protections for studies which 
contain higher risk levels. 
 For example, in order to eliminate the need for IRBs to consider the informational risks 
associated with a study, HHS proposes establishing mandatory data security and information 
protection standards for identifiable information.  Informational risks are the risks of harm 
resulting from a breach of confidentiality or the misuse of identifiable data.  Currently, without 
published standards to protect against informational risks, IRBs must assess the adequacy of data 
security procedures for each study individually.  A systematic review of 16 studies evaluating 
IRB variation was conducted by Abbott & Grady (2011) in which they found that the literature 
shows a great deal of variation across IRB reviews of the same protocol.
12
  By establishing 
mandatory standards that investigators must follow, variation among IRB reviews could be 
lessened.  However, it is the gains in IRB resources resulting from reduced oversight that HHS 
highlights with this proposed revision.  They believe that by establishing mandatory standards, 
the risk of harm resulting from breaches or misuses of information could be reduced to the extent 
that IRB review of these risks would not be necessary.  Instead, IRBs would solely confirm that 
investigators have standard protections in place opposed to assessing the adequacy of proposed 
procedures for each individual study. 
 Another proposed change by HHS which could ensure commensurate risk-based 
protections is the elimination of continuing review requirements for all minimal risk studies.  
This would include studies initially approved under expedited procedures, as well as studies 
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approved by a convened IRB which have progressed to the stages of research activities which 
present no more than minimal risk such as data analysis or long-term follow-up of subjects.  
Currently, all non-exempt studies regardless of risk are required to undergo continuing review at 
least once per year until all research activities are completed.  HHS questions whether or not 
annual review of studies which present no more than minimal risk of harm to subjects is an 
adequate use of IRB resources, especially when investigators already are required to submit any 
proposed changes and unanticipated problems for IRB review. 
 While the proposed changes of establishing mandatory data security and information 
protection standards and eliminating continuing review for minimal risk studies have potential to 
reduce regulatory burden for both IRBs and investigators, it is HHS‟s proposed changes to the 
categorization of exempt studies which could translate into the greatest amount of regulatory 
relief.  Currently, the Common Rule includes an exempt category for minimal risk studies which 
meet certain criteria.  This exempt classification generally covers studies involving the use of 
standard educational tests, survey or interview procedures, observations of public behavior and 
the review of existing data as long as the information obtained does not allow subjects to be 
identified and that any disclosure of the data outside of the research would not reasonably place 
subjects at risk of physical, psychological, financial or reputational harm.  The regulations do not 
require IRB review of studies that qualify for an exempt classification; however, federal 
guidance and best practices do recommend that the determination of whether or not a proposed 
research study meets the criteria for an exempt classification be completed by the IRB.  This has 
led to the common practice of IRBs requiring that exempt studies be submitted for some form of 
IRB approval, though this practice is not specifically mandated by the regulations.
13
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 To attempt to remedy this situation in which IRB resources potentially are being over-
used on research studies which pose the least risk, HHS is considering a complete re-evaluation 
of the exempt category.  What they propose is to replace the exempt classification with a new 
“Excused” category.  HHS explains that the change in terminology would clarify that these 
studies are no longer exempt from the regulations, but instead are excused from IRB review.  For 
example, investigators would still be required to follow the regulatory requirements such as the 
proposed mandatory data security measures; however, IRB review of the study prior to 
implementation would not be required.  In place of IRB review prior to implementation, HHS 
suggests that IRBs could institute a registration and tracking system to audit a portion of these 
studies.  In effect, investigators would first register their study with the IRB.  Then the 
investigator could either immediately begin research activities or begin after a short waiting 
period as determined by how the IRB decides to implement this change.  Once registered, the 
IRB would have the information necessary to confirm that the study meets the criteria for an 
“excused” classification, and could also conduct post-registration audits on select studies to 
ensure that the investigators are following their proposed protocols. 
 Furthermore, HHS proposes to expand the criteria previously defined for exempt 
categorization so that the new “excused” category would include a broader spectrum of minimal 
risk studies.  Specifically, they propose to remove the caveats regarding the identifiability of 
subjects and disclosure resulting in risks so that all studies involving standard educational tests, 
surveys, interviews and reviews of existing data involving competent adults would be included in 
the new “excused” category. 
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 If all of the proposed changes discussed above were to be incorporated into the Common 
Rule, the regulatory burden surrounding the conduct of research studies which pose no greater 
than minimal risk of harm to subjects could be significantly reduced.  To illustrate, consider an 
investigator who is proposing to conduct a survey of a sample of competent adults undergoing a 
surgery with the hopes of relieving back pain.  The investigator proposes to conduct a quality of 
life survey prior to surgery, six months post-surgery and then one year after surgery.  Assuming a 
within-subjects design, it would be necessary to record some sort of identifiable information for 
the purpose of matching subjects‟ responses.  Under the current regulations this study would be 
classified as either “exempt” or “expedited,” depending on the IRB‟s determination as whether 
or not the contents of the survey would be damaging to subjects if disclosed.  The investigator 
would be required to submit an application for review and approval prior to implementation of 
any research activities.  If the IRB approved the study under an expedited classification, the 
investigator would also be responsible for submitting an annual continuing review.  If HHS‟s 
proposed revisions were implemented, this study would qualify as an “excused” study and the 
investigator would only need to follow the mandated data security standards and register the 
study with the IRB.  The investigator would not need to wait for IRB approval before beginning 
the study, and would not need to submit any materials for annual continuing review. 
 This example is meant to illustrate how HHS‟s suggested revisions could reduce the 
regulatory burden for IRBs and investigators related to the review and conduct of minimal risk 
studies.  But HHS does not only address minimal risk studies in the proposed changes presented 
in the ANPRM.  Another aspect of IRB review that they have identified as being inefficient and 
needing enhancement are the regulations regarding IRB review of multi-site research studies. 
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Streamlining IRB Review of Multi-Site Studies 
 With the exception of studies of FDA-regulated medical devices, the regulations 
currently do not require that every participating site in a multi-site research study obtain approval 
from their local IRB.  While IRB approval of some form must be obtained, the regulations allow 
for the local IRB to rely on the IRB approval from another IRB rather than conducting their own 
review.  While some institutions use this flexibility in the regulations and rely on IRB approval 
from another institution or a central IRB, many still prefer to conduct their own review instead. 
 Loh & Meyer (2004) surveyed administrators at the then 125 accredited U.S. medical 
schools to examine their attitudes and perceptions of the use of central IRBs.
14
  The authors 
found that 76% of U.S. medical schools had never used central IRBs.  Of those schools that had 
never used a central IRB, the two main reasons cited for not using central IRBs were concerns 
about potential liability (74%) and a lack of local representation (86%).  However, of the 24% 
that had used central IRBs, most were pleased with the quality of the review (79%) and the level 
of human subjects protection performed (84%).  Most importantly, 79% reported that they were 
able to maintain excellent local oversight of the studies approved by the central IRB.  These 
results suggest that when administrators commit to using central IRBs they are very satisfied 
with the results.  However, with only 24% of U.S. medical schools committing to the use of 
central IRBs at the time of the survey, the concerns of liability and local representation clearly 
outweighed any prospects of optimizing local IRB resources. 
 In the ANPRM, HHS notes that the number of studies being conducted at multiple sites 
has increased over the years and is likely to continue to grow.  They also cite the common 
criticisms of multiple IRB reviews for one study: 
10 
 
In many cases, a local IRB for each institution does independently review the research 
protocol, informed consent documents and other materials, sometimes resulting in 
hundreds of reviews for one study.  When any one of these IRBs requires changes to the 
research protocol that are adopted for the entire study, investigators must re-submit the 
revised protocol to all of the reviewing IRBs.  This process can take months and can 
significantly delay the initiation of research projects…. Many commentators claim that 
multiple IRB reviews do not enhance the protection of human subjects and may, in fact, 
divert valuable resources from more detailed reviews of other studies.  Relevant local 
contextual issues (e.g., investigator competence, site suitability) pertinent to most clinical 
studies can be addressed through mechanisms other than local IRB review.  For research 
where local perspectives might be distinctly important (e.g., in relation to certain kinds of 
vulnerable populations targeted for recruitment) local IRB review could be limited to 
such consideration[s], but again, IRB review is not the only mechanism for addressing 
such issues.  The evaluation of a study‟s social value, scientific validity, and risks and 
benefits, and the adequacy of the informed consent document and process generally do 
not require the unique perspective of a local IRB.
2
 (pp. 44521-2)  
 The solution that HHS is contemplating is a revision to the regulations mandating that all 
participating sites in multi-site research studies rely on the IRB review of a single IRB.  They 
stress that this mandate would not relieve institutions of their responsibility to ensure that 
research being conducted at their site follows regulations for protecting human subjects, but it 
would eliminate formal IRB review at each participating site.  Recognizing that, as Loh & Meyer 
(2004) found, one of the main concerns institutions have about relying on external IRBs is 
related to liability, HHS agrees that any mandate requiring single IRB review of multi-site 
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studies must be accompanied with changes to the enforcement of regulations which would hold 
external IRBs accountable for regulatory requirements.  Again, institutions would still be 
required to ensure that the conduct of studies at their sites follows regulations, but with these 
revisions they would not be held responsible for regulatory decisions made by the IRB. 
 Similar to the proposed changes for ensuring risk-based protections, HHS‟s suggestions 
on how to streamline the IRB review of multi-site studies clearly emphasize a reduction in the 
amount of scrutiny a study currently receives during initial IRB review.  Proposing changes 
which would allow investigators to register “excused” studies and mandate single IRB review for 
multi-site studies could result in potentially significant reductions in both regulatory burden and 
delays in the initiation of research.  The other theme that is inherent within these proposed 
changes is that HHS‟s intent is also to enhance protections of human subjects.  It is clear that 
HHS believes that the current level of scrutiny during initial review does not enhance protections 
as much as actively monitoring studies while they are being conducted.  Hence, proposing to 
allow investigators to register “excused” studies is accompanied with a proposal to implement an 
auditing system post-registration; and mandating single IRB review for multi-site studies is 
paired with a reminder that eliminating IRB review does not relieve institutions of their 
responsibilities to ensure the conduct of the study follows regulations.  This emphasis on revising 
the regulations in order to allow IRBs to focus on areas that significantly affect the safety of 
human subjects is also inherent in HHS‟s suggestions for improving the informed consent 
process. 
Improving Informed Consent 
 While many of the criticisms of the regulations and the current IRB system are centered 
around perceived bureaucracy and inefficiencies, research suggests that the area that the subjects 
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themselves, and parents of pediatric subjects, would like to see improved is the informed consent 
process.
15,16
  Joffe et al. (2001) found that even when clinical trial subjects were satisfied with 
the informed consent process, the majority did not truly understand the information presented to 
them.
17
  Additional criticisms suggest that consent forms have become too long and much too 
complicated for the average subject to understand.
18,19
  Some critics have attributed the increased 
length of consent forms to language that has been added primarily for the protection of the 
institution rather than the subject.
20
 
 Currently, the Common Rule defines eight items that are required to be included in 
informed consent forms when applicable: a statement that the study involves research, a 
description of any foreseeable risks, a description of any possible benefits, a disclosure of 
appropriate alternative procedures or courses of treatment, a statement describing the extent to 
which confidentiality will be maintained, an explanation of whether compensation is available if 
injury occurs, contact information in case of questions and an explicit statement that participation 
in the study is voluntary.  The only language that is specifically prohibited by the regulations is 
exculpatory language in which the subject is asked to waive any legal rights or release the 
investigator or institution from any liability. 
 To enhance the effectiveness of informed consent HHS is considering revising the 
regulations to include more specific standards for the content of informed consent forms.  Their 
suggestions include: 
 1) Prescribing appropriate content that must be included in consent forms, with greater 
specificity than is provided in the current regulations; 2) restricting content that would be 
inappropriate to include in consent forms; 3) limiting the acceptable length of various 
sections of a consent form; 4) prescribing how information should be presented in 
13 
 
consent forms, such as information that should be included at the very beginning of the 
consent form, or types of information that should be included in appendices and not in the 
main body of the consent form; 5) reducing institutional „boilerplate‟ in consent forms 
(that is, standard language that does little to genuinely inform subjects, and often is 
intended to primarily protect institutions from lawsuits); and 6) making available 
standardized consent form templates, the use of which could satisfy applicable regulatory 
provisions.
2
 (p. 44523) 
 Reactions to the proposed changes outlined in the ANPRM already range from 
excitement to reservation.  The Society for Clinical and Translational Science applauds the 
proposed revisions and exclaims that “these changes in the Common Rule will be a common 
good”
21
 (p. 313).  Alternatively, the Association for the Accreditation for Human Research 
Protection Programs (AAHRPP) has stated that they believe HHS needs “to alter its approach to 
the proposed rulemaking so that the primary purpose is to protect human research participants…. 
Although the ANPRM states that one of the intentions is to enhance protections for research 
participants, the apparent primary purpose of the proposed rulemaking seems to be to reduce 
burden on researchers”
22
 (p. 3). 
What we don‟t know yet is how IRB directors perceive these proposed changes.  Once 
revisions to the Common Rule are finalized, IRB directors and personnel will be tasked with 
digesting the final revisions and coordinating policies and procedures in order to translate those 
revisions into realized enhancements.     
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METHODS 
This research study was approved by the Human Subjects Committee at the University of 
Kansas Medical Center (KUMC) under exempt category b(2).  No information was collected that 
would allow the investigator to link responses to individual subjects.  Study data were collected 
and managed using REDCap electronic data capture tools hosted at KUMC.
23
  REDCap 
(Research Electronic Data Capture) is a secure, web-based application designed to support data 
capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit 
trails for tracking data manipulation and export procedures; 3) automated export procedures for 
seamless data downloads to common statistical packages; and 4) procedures for importing data 
from external servers.   
 Sample 
 Invitations to participate in this online survey research study were sent to a convenience 
sample of the IRB directors of the top 200 research universities as identified by 2010 Annual 
Report of The Center for Measuring University Performance.
24
  Email addresses were obtained 
by reviewing each university‟s IRB website.  For the purpose of this study, IRB director was 
operationally defined as the individual responsible for the day to day function of the IRB and 
supporting staff.  Given the variation in the titles given to this administrative position, selection 
of individuals not specifically identified as IRB directors were prioritized in the following order: 
Director of Research Integrity, Director of Research Compliance, IRB Manager, Vice President 
of Research, IRB Coordinator and IRB Analyst.  Additionally, the email invitation included the 
following statement to better reach the target population: “If you are not the IRB Director at your 
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institution, or the individual responsible for the function of the IRB and supporting staff, I would 
appreciate if you could please forward this invitation to the correct person.”   
Some of the top 200 research universities shared institutional affiliations and therefore 
IRBs.  Also, several of the universities had more than one IRB.  Therefore the total number of 
206 potential subjects were identified and sent email invitations to participate.  
Survey Instrument 
 The survey was comprised of six sections.  The first two sections were designed to obtain 
participant and institutional demographics.  Sliding Likert scales which allowed subjects to rate 
their level of agreement on a continuous range from 0-100 (0 = strongly disagree, 50 = neither 
agree or disagree, 100 = strongly agree) were used to query subjects about their perceptions of 
the current regulations.  The third section included questions related to multi-site research studies 
and the use of central IRBs.  The survey questions used by Loh & Meyer (2004) to survey U.S. 
medical schools about the use of central IRBs were replicated in order to examine if use of, 
attitudes toward and perceptions of central IRBs have changed in the last seven years.  Then 
sliding Likert scales were used to query subjects about the proposed revisions to the review of 
multi-site research studies as proposed in the ANPRM.   
The fourth and fifth sections of the survey used sliding Likert scales to query subjects 
about their level of agreement with the proposed changes regarding ensuring risk-based 
protections and improving informed consent, respectively.  Throughout the sections about the 
proposed revisions subjects were also presented open-ended questions to allow for detailed 
comments.  The final section of the survey included an open-ended question asking subjects to 
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provide any additional opinions on the other four areas of the ANPRM that were not covered in 
the current study.  The complete survey is available in Appendix I. 
Statistical Analysis 
 Data were analyzed using IBM SPSS Statistics version 20.  Descriptive statistics were 
used to report participant and institutional characteristics as well as Likert scale values.  Due to 
the skew of the Likert scale values, these data are described by medians ( ) and interquartile 
ranges (IQR), opposed to means and standard deviations. 
Nonparametric tests were used to examine both whether perceptions (sliding Likert 
values) were significantly different amongst categorical variables and to examine significant 
correlations between categorical variables.  The Mann-Whitney test was used for examining 
Likert values against categorical variables with only two possible values: type of studies 
reviewed (“biomedical and/or social/behavioral” or “social/behavioral only”), classification as an 
academic medical center (yes or no) and years of experience in human subjects protections (“5 
years or less” or “more than 10 years”).  The Kruskal-Wallis test was used examining Likert 
values against categorical variables with more than two possible values: number of active studies 
and average time to approval for the local IRB.  Fisher‟s Exact Test was used in order to test for 
significant associations between categorical variables: use of central IRBs (yes or no), type of 
studies reviewed (“biomedical and/or social/behavioral” or “social/behavioral only”), 
classification as an academic medical center (yes or no) and number of currently active studies. 
RESULTS 
 A total of 69 evaluable responses were collected following 206 invitations (33.5%).  A 
total of 77 subjects submitted responses, however 8 subjects were removed from analysis 
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because they only responded to the personal characteristic questions and did not complete any of 
the questions regarding the proposed revisions to the regulations. 
 Of the 69 evaluable responses, 63 subjects have been working in human subjects 
protections for more than 5 years (91.3%), and 49 subjects have been in charge of oversight of 
the function of the IRB for 4 years or more (71.0%) (see Table 1).  Almost all subjects (95.7%) 
had familiarized themselves with the ANPRM prior to participation.   
The number of currently active studies overseen by the subjects‟ IRBs varied with 33 
subjects reporting that their IRB oversees 1000 active studies or less (47.8%) while 15 subjects 
reported that their IRB oversees more than 2500 active studies (21.7%).  The 35 subjects from 
academic medical centers comprised 50.7% of the sample and 53 subjects reported that their IRB 
review both biomedical and social/behavioral research studies (76.8%).  A total of 55 subjects 
reported that the average time to approval for studies submitted to their local IRB was 6 weeks or 
less (79.7%). 
Using the sliding Likert scales ranging from 0-100, subjects reported that on average they 
believe that the current regulations promote effective protections of human subjects (  = 75, IQR 
= 62.75 – 83.00) and that the current regulations promote efficient review of human subjects 
protections (  = 54, IQR = 37.00 – 75.00) (see Table 2).  Overall, subjects did not agree that the 
current regulations are adequate and do not need revised (  = 32, IQR = 15.75 – 50.00); however 
subjects who direct IRBs that solely review social/behavioral studies believe that the current 
regulations are adequate and do not need to be revised (  = 55, IQR = 39.75 – 74.00).  This was 
significantly different (U = 150.50, p < 0.005) than subjects who oversee IRBs that review 
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Table 1: Characterization of Sample Population (n = 69) 
Variable f (%) 
Years responsible for oversight of IRB  
- Less than 1 year 3 (4.3%) 
- 1-3 years 17 (24.6%) 
- 4-6 years 20 (29.0%) 
- 7-9 years 12 (17.4%) 
- 10 years or more 17 (24.6%) 
  
Total years working in human subjects protections  
- Less than 1 year 0 (0.0%) 
- 1-5 years 6 (8.7%) 
- 6-10 years 30 (43.5%) 
- 11-15 years 18 (26.1%) 
- 15 years or more 15 (21.7)% 
  
Familiarized with ANPRM prior to survey  
- Yes 66 (95.7%) 
- No 3 (4.3%) 
  
Number of currently active human subjects research studies  
- Less than 500 studies 13 (18.8%) 
- 501-1000 studies 20 (29.0%) 
- 1001-1500 studies 6 (8.7%) 
- 1501-2000 studies 7 (10.1%) 
- 2001-2500 studies 7 (10.1%) 
- More than 2500 studies 15 (21.7%) 
- Not able to answer* 0 (0.0%) 
- Missing** 1 (1.4%) 
  
Type of human subjects research studies reviewed by IRB  
- Biomedical only 3 (4.3%) 
- Social/Behavioral only 12 (17.4%) 
- Both biomedical and social/behavioral 53 (76.8%) 
- Missing** 1 (1.4%) 
  
Is your institution classified as an academic medical center?  
- Yes 35 (50.7%) 
- No 33 (47.8%) 
- Missing** 1 (1.4%) 
  
Average reported time to approval for submissions to the local IRB  
- Less than 2 weeks 6 (8.7%) 
- 15-21 days 11 (15.9%) 
- 22-28 days 16 (23.2%) 
- 4-6 weeks 22 (31.9%) 
- 6 weeks – 3 months 4 (5.8%) 
- More than 3 months 0 (0.0%) 
- Not able to answer 4 (5.8%) 
- Missing** 6 (8.7%)    
*For certain variables which required that the subject had completed previous benchmarking calculations prior to completing the 
survey, subjects were given the option to answer “Not able to answer.” **Subjects were not required to complete all questions in 
the survey.  “Missing” refers to frequency of subjects who did not supply an answer to the question.  
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Table 2: Perceptions of Current Regulations Regarding the Protections of Human Subjects (n = 69) 
Values given are subject‟s scores (0-100) on a sliding Likert scale which ranged from “Strongly Disagree” to 
“Strongly Agree.”  The higher the value, the greater the level of agreement with the statement.  
Statement Mean Median SD Interquartile 
Range 
Missing* 
The current regulations promote effective 
protections for human subjects.  
71.04 75 16.72 62.75 – 83.00 1 
      
The current regulations promote efficient 
review of protections for human subjects. 
55.25 54 22.47 37.00 – 75.00 2 
      
The current regulations are adequate 
and DO NOT need to be revised. 
37.21 32 27.74 15.75 – 50.00 1 
      
*Subjects were not required to complete all questions in the survey.  “Missing” refers to frequency of subjects who 
did not supply an answer to the question.  
 
biomedical studies only or both biomedical and social/behavioral studies (  = 30, IQR = 9.00 – 
40.00).       
Ensuring Risk-Based Protections 
 While subjects agreed with the proposed revisions to eliminate continuing review for 
expedited studies (  = 75, IQR = 32.25 – 90.75), and full committee studies which have 
progressed to data analysis only (  = 90, IQR = 68.00 – 99.00)  or long-term follow-up only (  = 
75, IQR = 50.00 – 91.75), they did not agree with concept of mandatory data security standards 
replacing IRB review of informational risks (  = 27, IQR = 10.00 – 56.00)  (see Table 3).  The 
proposed revisions which subjects disagreed with the most on average were those pertaining to 
the new “excused” category.  Subjects did not agree that allowing investigators to register their 
“excused” studies prior to implementation was a good idea (  = 13, IQR = 0.00 – 55.00), and if 
this revision were to be implemented 35 subjects reported that they believe a week long or more 
waiting period before an investigator could begin a study following registration with the IRB  
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Table 3: Perceptions of the Proposed Revisions Regarding Ensuring Risk-BasedPprotections (n = 69) 
Values given are subject‟s scores (0-100) on a sliding Likert scale which ranged “Strongly Disagree” to “Strongly 
Agree.”  The higher the value, the greater the level of agreement with the statement.  
Statement Mean Median SD Interquartile 
Range 
Missing* 
Mandatory data security standards      
If mandatory data security and information 
protections standards were implemented, 
indicate how comfortable you would be with the 
IRB no longer being responsible for review of a 
research study‟s plan for minimizing 
information risks.**  
36.02 27 29.60 10.00 – 56.00 10 
      
Elimination of continuing review for minimal 
risk studies 
     
I am comfortable with the IRB no longer 
conducting continuing review on… 
     
- Expedited studies  62.50 75 32.83 32.25 – 90.75 9 
- Full review studies in data analysis only 77.84 90 27.33 68.00 – 99.00 8 
- Full review studies in long-term follow-up 
only 
67.68 75 29.47 50.00 – 91.75 9 
      
Changing “Exempt” to “Excused”      
Allowing investigators to begin research activities 
for “excused” studies without formal IRB review 
prior to implementation is a good idea. 
29.30 13 35.22 0.00 – 55.00 8 
Shifting resources from pre-implementation 
review to post-implementation monitoring for 
“excused” studies would be a more efficient use of 
resources. 
30.02 22 32.42 1.00 – 50.00 8 
Shifting resources to post-implementation 
monitoring would result in more effective 
protections of human subjects than pre-
implementation IRB review. 
29.29 20 30.55 2.00 – 50.00 10 
Including all survey-type research with competent 
adults into this new “excused” category, regardless 
of the type of data being collected, is a good idea. 
44.22 50 33.90 8.25 – 70.00 11 
      
Variable Frequency Percentage 
If a waiting period was required before an investigator could start 
an excused study, how long of a waiting period do you think would 
be appropriate?  
  
- Less than 3 days 8 11.6% 
- 4-6 days 12 17.4% 
- 7-10 days 14 20.3% 
- 11-14 days 13 18.8% 
- More than 14 days 8 11.6% 
- Missing* 14 20.3% 
*Subjects were not required to complete all questions in the survey.  “Missing” refers to frequency of subjects who 
did not supply an answer to the question.  
**For this survey question Likert scale ranged from “Very Uncomfortable” to “Very Comfortable.” 
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would be appropriate (50.7%).  Overall, subjects did not agree that shifting resources from pre-
implementation review to post-implementation monitoring would be more effective (  = 20, IQR 
= 2.00 – 50.00) or more efficient (  = 22, IQR = 1.00 – 50.00).  However, subjects with 5 years 
of experience or less agreed with the proposed revisions regarding mandatory data security and 
the proposed “excused” category which was significantly different that subjects with more than 
ten years of experience (see Table 4).  
Use of Central IRBs and Comparison to Loh & Meyer (2004) 
In 2004, Loh & Meyer found that 21% of medical schools surveyed had used a central IRB.
14
  
Seven years later, 94% of subjects in the current study who oversee IRBs at academic medical 
centers (n=35) and 58% of all subjects (n=69) report that they have used a central IRB (see Table 
5).  However, fewer subjects in the current study from academic medical centers agree that the 
central IRBs used provide quality protections of human subjects (57%) and quality scientific 
review (46%) compared to subjects from the previous study (84% and 79%, respectively) (see 
Table 6).  Reasons for not using a central IRB were not able to be compared between studies 
because only 2 subjects in the current study from academic medical centers reported that they 
had never used a central IRB (5.7%).  Use of central IRBs was significantly correlated with the 
review of biomedical research (rs = .475, p < 0.001), classification as an  academic medical 
center (rs = .742, p < 0.001) and greater numbers of currently active studies (rs = .457, p < 0.001) 
(see Table 7). 
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Table 4: Mann-Whitney Comparison of Perceptions of Proposed Revisions to the Regulations in Regards to 
Mandatory Data Security Standards and the New “Excused” Category by Years of Experience in Human 
Subjects Protection. 
If mandatory data security and information protections standards were implemented, 
indicate how comfortable you would be with the IRB no longer being responsible for 
review of a research study’s plan for minimizing information risks.* 
Sample n ( , IQR) Test Statistic Sig. (2-sided) 
5 years or less 5 (77.00, 34.50 - 84.50) 26.00 p < 0.05 
More than 10 years 27 (20.00, 9.00 – 43.00)   
     
Allowing investigators to begin research activities for “excused” studies without formal 
IRB review prior to implementation is a good idea. 
Sample n ( , IQR) Test Statistic Sig. (2-sided) 
5 years or less 6 (73.00, 21.25 – 100.00) 18.00 p < 0.05 
More than 10 years 27 (2.00, 2.00 – 25.00)   
     
Shifting resources from pre-implementation review to post-implementation monitoring for 
“excused” studies would be a more efficient use of resources. 
Sample n ( , IQR) Test Statistic Sig. (2-sided) 
5 years or less 6 (37.50, 24.50 – 100.00) 34.50 p < 0.05 
More than 10 years 28 (10.50, 1.00 – 35.25)   
     
Shifting resources to post-implementation monitoring would result in more effective 
protections of human subjects than pre-implementation IRB review. 
Sample n ( , IQR) Test Statistic Sig. (2-sided) 
5 years or less 6 (55.50, 19.50 – 100.00) 30.00 p < 0.05 
More than 10 years 27 (6.00, 6.00 – 30.00)   
*For this survey question Likert scale ranged from “Very Uncomfortable” to “Very Comfortable.” 
  
Table 5: Use of Central IRBs 
Has your institution ever used a central IRB? n Frequency Percentage 
Total sample 69   
- Yes  40 58.0% 
- No  28 40.6% 
- Missing  1 1.4% 
    
Academic medical centers 35   
- Yes  33 94.3% 
- No  2 5.7% 
    
Other types of institutions* 33   
- Yes  7 21.2% 
- No  26 78.8% 
* “Other types of institutions” includes all subjects who replied “No” to “Is your institution 
classified as an academic medical center.” 
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Table 6:  Attitudes Towards Using a Central IRB as Reported in Loh & Meyer (2004) (n=21) Compared to 
the Current Study Results (n=35).* 
Statement Strongly 
Agree 
(%) 
Agree 
(%) 
Disagree 
(%) 
Strongly 
Disagree 
(%) 
Unable to 
Answer 
(%) 
Use of a central IRB has shortened the time to 
approval.  
     
- Loh & Meyer (2004) 11 42 11 21 16 
- Current study 14 23 23 17 23 
      
We are pleased with the quality and level of the 
scientific review performed by the central IRB.  
     
- Loh & Meyer (2004) 11 68 0 5 16 
- Current study 17 29 9 9 37 
      
We are pleased with the human subjects 
protection review performed by the central IRB.  
     
- Loh & Meyer (2004) 16 68 5 5 5 
- Current study 17 40 9 9 25 
      
We are able to maintain excellent local oversight 
for studies approved by a central IRB.  
     
- Loh & Meyer (2004) 11 68 5 5 11 
- Current study 23 23 17 14 23 
      
Use of a central IRB has attracted industry 
sponsors.  
     
- Loh & Meyer (2004) 0 5 32 16 47 
- Current study 17 9 11 3 60 
      
*Data for the current study was collected using a sliding Likert scale ranging from 0-100.  In order to compare 
results to Loh & Meyer (2004), the current data was grouped into corresponding categories: 0-24 = “Strongly 
Disagree,” 25-49 = “Disagree,” 51-75 = “Agree,” 76-100 = “Strongly Agree,” 50 and missing values = “Unable to 
Answer.” 
 
Streamlining IRB Review of Multi-Site Studies 
 Though subjects reported on average that they agree that multiple IRB reviews of multi-
site studies significantly delays the initiation of research (  = 75, IQR = 65.00 – 91.25), they also 
believe that local IRB review of multi-site studies adds to the protection of local human subjects 
(  = 64, IQR = 35.00 – 75.00) (see Table 8).  In regards to the proposed revisions by HHS to 
mandate single IRB review of multi-site studies, subjects reported that they would agree with 
this new regulation as long as the IRB of record is held regulatorally accountable (  = 74, IQR =    
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50.00 – 90.75) and legally liable (  = 75, IQR = 50.00 – 95.50).  Subjects were concerned, 
however, with how the IRB of record would be determined (  = 72, IQR = 55.00 – 96.00). 
Table 7: Significant Associations Between Use of Central IRBs and Local IRB Demographics. 
 Review 
biomedical 
research 
 (yes or no) 
Academic 
medical 
center  
(yes or no) 
Number of 
currently 
active 
studies.* 
Use of central 
IRBs (yes or no) 
Sig. (2-tailed)  p < .001 p < .001 p < .005 
N 68 68 68 
* Number of currently active studies were categorized as “less than 500,” “501-1000,” “1001-1500,” 
“1501-2000,” “2001-2500,” and “more than 2500.”   
 
 
Table 8: Perceptions of the Proposed Revisions Regarding Streamlining IRB Review of Multi-Site Studies (n = 
69) 
Values given are subject‟s scores (0-100) on a sliding Likert scale which ranged “Strongly Disagree” to “Strongly 
Agree.”  The higher the value, the greater the level of agreement with the statement.  
Statement Mean Median SD Interquartile 
Range 
Missing* 
Multiple IRB reviews of multi-site studies 
significantly delays the initiation of research. 
75.02 75 19.72 65.00 – 91.25 7 
      
Local IRB review of a multi-site study adds to the 
protection of local human subjects. 
57.37 64 25.47 35.00 – 75.00 10 
      
If single IRB review was mandated for all multi-site 
studies, I‟m concerned about how the IRB of record 
would be selected. 
69.07 72 28.95 55.00 – 96.00 10 
      
I would agree with mandating single IRB review for 
multi-site studies as long as the IRB of record is held 
regulatorally accountable for their review. 
66.95 74 30.50 50.00 – 90.75 9 
      
I would agree with mandating single IRB review for 
multi-site studies as long as the IRB of record is held 
legally liable for their review. 
68.74 75 30.55 50.00 – 95.50 12 
      
*Subjects were not required to complete all questions in the survey.  “Missing” refers to frequency of subjects who 
did not supply an answer to the question.  
 
Improving Informed Consent 
 Overall, subjects agreed that the current regulations need to be revised to provide more 
specific guidance on acceptable content in informed consent forms (  = 77.50, IQR = 60.50 – 
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94.50) (see Table 9).  Of all the revisions to the regulations proposed by HHS, subjects most 
strongly agreed that the regulations need to be revised to account for the fact that informed 
consent forms have become too lengthy (  = 84, IQR = 66.00 – 100.00) and contain too much 
institutional “boilerplate” language (  = 81, IQR = 61.00 – 97.50).  
Table 9: Perceptions of the Proposed Revisions Regarding Improving Informed Consent (n = 69) 
Values given are subject‟s scores (0-100) on a sliding Likert scale which ranged “Strongly Disagree” to “Strongly 
Agree.”  The higher the value, the greater the level of agreement with the statement.  
Statement Mean Median SD Interquartile 
Range 
Missing 
The current regulations need to be revised to 
provide more specific guidance on acceptable 
content in informed consent forms. 
71.88 77.50 26.70 60.50 – 94.50 13 
      
Consent forms have become too lengthy and the 
regulations need to be revised to address this issue. 
77.68 84 24.33 66.00 – 100.00 12 
      
Consent forms today include too much information 
that is not pertinent to the subjects (e.g., 
institutional “boilerplate” language) and the 
regulations need to be revised to address this issue. 
75.70 81 24.43 61.00 – 97.50 12 
      
 
 
DISCUSSION 
The survey results of the current study show that IRB Directors are open to the idea of 
revising the regulations on protecting human subjects, but they do not agree with all of revisions 
proposed by HHS.  Clearly, the IRB Directors surveyed are not satisfied with the current state of 
informed consent forms and are in favor of adding more specific language to the regulations in 
order to better define acceptable content and shorten the overall length of the form.  One subject 
suggested the use of a “single page standardized consent document that explains what research is 
which is used for every study, because the concepts of research, voluntariness, informed consent, 
ability to opt-out are universal.”  In the ANPRM, HHS proposes creating standard consent form 
templates which satisfy regulatory requirements and also specify an appropriate order of content.  
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One template option HHS could consider would be to create a standardized section, as suggested 
by this subject, which describes the basic tenants of participation in human subjects research and 
could be required to precede protocol specific information to ensure that all subjects are 
presented with the same baseline information.  Standard language such as this would not be 
difficult to incorporate into current institutional templates. 
The limited requirements in the current regulations have given institutions a great deal of 
flexibility in tailoring consent forms to meet the needs of their subject community.  However, 
some critics believe that that flexibility has resulted in consent forms which have deviated too far 
from their intended purpose which is to provide subjects and parents with the appropriate 
information to facilitate their ability to make the best decisions possible about participation.
18, 19
  
Given the results of past research,
15, 16, 17
 improvements to the length and complexity of informed 
consent forms may be most appreciated by subjects and parents, much less IRB Directors and the 
IRB members responsible for review of these forms.
 
  
As with informed consent, subjects reported that they generally agreed with the proposed 
revisions regarding the streamlining of IRB review for multi-site studies; however, their open 
ended comments focused primarily on their concern for how the IRB of record would be 
determined and whether or not this mandate would truly reduce delays to the initiation of 
research.  In the ANPRM, HHS acknowledged the difficulty in effectively regulating the 
selection of a single IRB of record and asked for comments on how to avoid “inappropriate 
forms of „IRB shopping‟ – intentionally selecting an IRB that is likely to approve the study 
without proper scrutiny – be prevented?”
2
 (p 44522)   HHS does not, however, specifically 
address how they envision this mandate reducing review times other than noting that the process 
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of responding to multiple IRBs with revised protocols can cause delays.  A concern raised by 
several subjects is that the time spent by the IRB reviewing a multi-site trial will just be replaced 
by other compliance committees such as radiation safety, biosafety, privacy, and conflict of 
interest.  Fifty eight percent of subjects reported that their institution requires approval from 
other institutional committees prior to the initiation of research studies approved by central IRBs.  
One subject argued that “the belief that use of central IRBs is going to markedly expedite the 
IRB review and approval process totally ignores the requirement for multiple non-IRB 
committee reviews… and many of these committees have slower turnaround than the IRB.” 
Mandating single IRB review for multi-site studies would be a bold revision which would 
entail a great deal of planning prior to implementation.  Though it stands to reason that this 
mandate could reduce delays and regulatory burden in terms of IRB review, as currently 
proposed it would not directly address all of the compliance factors which lead to delays in the 
initiation of multi-site studies.  If HHS‟s intentions are to truly reduce delays to initiation of 
research they will need to consider bolstering this section of the regulations with specific 
guidance related to institutional reviews beyond the IRB.        
Industry sponsors would undoubtedly be elated with this mandate for single IRB review, 
but as many subjects suggested, an elaborate regulatory infrastructure encompassing the IRB and 
other institutional committees would need to be designed and tested prior to implementation.  As 
one subject suggested, “funds must be dedicated to studying and testing models which explore 
how to select lead IRBs, how to submit and share information and how to allocate risk and 
liability.”  I would also add an additional objective to this list to examine in more detail the times 
to approval for central IRBs compared to local reviews with an emphasis on including other 
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institutional committees in the outcome of total time to approval.  Though use of central IRBs 
has increased among academic medical centers, 41% of subjects reported that their institutions 
have never used a central IRB.  While institutions that have used central IRBs will already have 
policies and procedures in place for how to rely on outside IRBs and perform other necessary 
institutional reviews, institutions who have not yet used a central IRB and intend to participate in 
multi-site research would incur an additional administrative burden to meet these requirements.  
The research on testing models of implementation could greatly assist these institutions during 
their transition.   
Though subjects had concerns about certain aspects of the proposed revisions for 
improving informed consent and streamlining IRB reviews of multi-site studies, they did agree 
with the overall need for revision to the regulations.  The same cannot be said about the proposed 
revisions to ensure risk-based protections.  While subjects were in favor of eliminating 
continuing review for expedited studies and full committee studies which have progressed to 
data analysis or long-term follow-up, they did not agree with eliminating IRB review of 
informational risks by establishing mandatory data security standards and strongly disagreed 
with the concepts behind the proposed “excused” category.  When looking at the proposed 
revisions regarding ensuring risk-based protections as a whole, HHS‟s suggestions illustrate a 
shift in the philosophy of human subjects protections for minimal risk studies away from pre-
implementation review and approval to registration and post-implementation monitoring; A 
philosophy with which most subjects in the current study clearly do not agree.  Interestingly 
though, there was a significant difference in agreement with allowing investigators to register 
“excused” studies when analyzed by years of experience in human subjects protections.  Subjects 
with 5 years of experience or less agreed with allowing investigators to register “excused” 
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studies while subjects with more than 10 years experience strongly disagreed.  A limitation of the 
current study is that only 6 subjects reported having 5 years of experience or less, so the validity 
of this comparison should be questioned until a larger sample can be examined.    
It is important to remember that the types of studies included in the new “excused” 
category are studies that previously would have been classified as “exempt,” plus formally 
“expedited” survey studies involving competent adults which present no reputational, financial 
or legal risks.  This means that even if the data were to be accidentally released it would not 
result in any harm to the subject.  For a study such as this, what would be the purpose of an IRB 
review beyond confirmation that the investigator made a correct risk assessment?  Why would a 
registration process to conduct this confirmation not be adequate?  If volume is an issue and IRB 
Directors would like time to make this confirmation before investigators begin research 
activities, a short waiting period of a couple of days seems reasonable.  In fact, several subjects 
reported that their current exempt reviews are completed within two days, so a mandatory 
waiting period longer than two days would actually hinder their current efficiency.  So why are 
subjects so adamantly against this proposed revision? 
Comments from subjects who did not agree with the registration of “excused” studies 
predominantly centered on a belief that investigators often times do not make correct 
determinations regarding the possible risks of their research.  As one subject implored, 
“Researchers demonstrate an inability to correctly categorize research now; concerned that they 
will be able to do so in the future.”  Similarly, another subject believed that “many investigators 
will misapply the standards for the 'excused' category,” doubted that investigators “will always 
assess the risks of what they are doing in an appropriate way,” and went as far as to suggest that 
30 
 
“there will be abuse of determining just who is competent” (in reference to the “excused” 
category including all types of surveys with competent adults).  Given the tenor of these 
comments, an important question to ask is: Are these realistic concerns that are based on years of 
experience and are evidence enough that a registration process for minimal risk studies will put 
subjects at increased risk of harm?  Or, are these past experiences leading to irresponsible 
assumptions that could hinder the progress of minimal risk research? 
In order to believe that a registration process for “excused” studies would not work one 
must either believe that (1) investigators as a whole cannot be trusted to consistently make 
correct decisions as to the risk-level of their study, or that (2) IRB review and approval of these 
minimal risk studies prior to implementation is necessary in order to protect subjects from 
possible risks.  Factors that could contribute to an inability of investigators to make correct 
decisions about the risk-level of their study would be (1) inadequate education on determining 
risk-levels, (2) a disregard for the importance of compliance to regulations and (3) conflicts of 
interest.   
It should be safe to assume that investigators have the capacity to learn how to properly 
classify the possible risks of their studies.  Chances are their fields of study are more complex in 
nature than the federal regulations.  Educational materials can be easily created and presented to 
investigators to sufficiently educate them on the risk criteria of the “excused” category.  A more 
realistic concern may be whether investigators believe that mastering this categorization in order 
to ensure compliance with the regulations is important enough to warrant their time and effort.  
As one subject commented, “Investigators don't have the time or knowledge to become educated 
sufficiently on the categorical determinations or requirements and will make many errors.”  It is 
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true that time is often an incredibly valuable commodity for many investigators, so further 
investigation may be warranted into examining investigators‟ perceptions of the importance of 
compliance in terms of minimal risk research.   
The most important discussion about factors which could lead to an investigator 
incorrectly categorizing the risk level of study, would be the discussion of whether there are 
possible conflicts of interest in investigators making these determination about their own resarch.  
One subject argued against registration because he/she believed that “investigators are inherently 
conflicted when it comes to assessing our own work.”  Given the competitive nature of research, 
there is incentive for investigators to choose whichever review category provides the shortest 
delay to initiation of their research.  Research into the validity of investigators‟ assessments of 
the risk of their own research could provide valuable information to assist HHS in their 
considerations of their proposed revisions.   
As with a belief that investigators cannot be trusted to make their own risk assessments, 
another reason to believe that registration would not be adequate would be the argument that IRB 
review of these minimal risk studies would be necessary to ensure adequate protections of 
subjects.  In other words, after controlling for the first assumption of incorrect categorization of 
risk, one would have to believe that the possible risks involved in this category of research can 
only be mitigated by IRB review and approval prior to implementation.  To simplify even 
further, if the IRB doesn‟t review the study before the investigator begins, subjects are more 
likely to be harmed.   
Again, to reiterate, the types of studies that would be included in this category are studies 
that present virtually no risk.  Assuming that a study truly meets the criteria for the “excused” 
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category and the investigator does not deviate from the proposed activities, what are the 
additional protections that could be gained which would necessitate IRB review prior to 
implementation?  Even if there is a concern about deviation from the protocol, this is not an issue 
that can be mitigated at initial review.  Post-implementation monitoring would be necessary to 
identify and correct risk associated with deviation from the protocol.      
 
CONCLUSIONS 
Given the areas of the regulations targeted for revision in the ANPRM, HHS assumedly 
recognizes that any gains in the effectiveness and efficiency of human subjects protections must 
begin with regulatory relief.  If, as critics have been arguing for years, the pendulum of human 
subjects protections has swung to the extremes of bureaucratic over-regulation, the 
implementation of HHS‟s proposed revisions would certainly provide a needed correction to 
more balanced regulations.  In the end, any actual realization of gains will be dependent upon 
how IRB Directors interpret the final revisions and then adapt their administrative processes.   
The objective of the current study was to assess IRB Directors‟ perceptions of the 
proposed revisions and identify any barriers to implementation.  The results of the study showed 
that IRB Directors recognize the need for revisions to the regulations and generally agreed with 
mandating single IRB review for multi-site studies, eliminating continuing review for minimal 
risk studies and efforts to improve informed consent forms.  On the other hand, subjects did not 
agree with the proposed revisions in regards to the new “excused” category and more specifically 
with the idea of allowing investigators to register these studies rather than submit for IRB review 
and approval prior to beginning research activities.  The main barrier to acceptance of this 
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proposed revision is a distrust of investigators to adequately assess the risk associated with their 
study.   
Mandated revisions such as single IRB review of multi-site studies, and more specified 
regulations such as those proposed for informed consent forms, leave little room for flexibility.  
However, if IRB Directors do not agree with the proposed revisions to ensure risk-based 
protections, such as the new “excused” category, they are free to implement institutional 
standards that are more stringent then the regulations themselves.  If HHS believes that the 
current regulatory burden associated with minimal risk studies is unbalanced, the results of the 
current study suggest that more work needs to be done to convince IRB Directors that 
investigators can be trusted to conduct minimal risk research with minimal oversight.  
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APPENDIX: Survey Instrument 
Please complete the survey below.  If you would like to save your progrss and return to complete 
later, click on "Save and Return Later" at the bottom of the page. 
Introduction 
Thank you for choosing to participate in this research study. This research study is being 
conducted through the University of Kansas Medical Center by Ryan McDowell, BS, CIP for 
satisfaction of thesis requirements for the Master of Science in Clinical Research. 
In July, the Department of Health & Human Services (DHHS) released an advance notice of 
proposed rulemaking (ANPRM) titled Human Subjects Research Protections: Enhancing 
Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators. 
The notice includes proposed changes to the federal regulations regarding human subjects 
research protections. The following survey will ask your opinion on a selection of the proposed 
changes which would have the greatest effect on how IRB offices process human subjects 
research submissions. In addition, you will be asked questions about the number and types of 
human subjects research studies reviewed by your IRB as well your institution's use of central 
IRBs. 
The IRB Directors of the top 200 research universities in the United States are being asked to 
participate in this research study. The survey will take approximately 20-25 minutes to complete. 
You may exit the survey at any time and return to complete at a later time. 
In order to minimize the chance of a breach of confidentiality, you will not be asked to provide 
any identifiable information. In addition, the survey program being used will not record any 
electronic identification information from your computer (e.g., IP address). It is hoped that the 
information gained will help the investigators learn more about how IRB Directors perceive the 
proposed changes to federal regulations. 
If you have any questions before or after completion of this survey, please contact Ryan 
McDowell at rmcdowell@kumc.edu. 
 
 
 
To continue to the survey, please click "Next Page" below. 
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Participant Information 
For how many years have you been responsible for oversight of the IRB(s) at your institution? 
Less than 1 year 
1-3 years 
4-6 years 
7-9 years 
10 years or more 
 
Including the time spent in your current position, for how many years have you been working in 
human subjects protection? 
Less than 1 year 
1-5 years 
6-10 years 
11-15 years 
15 years or more 
 
Please rate your level of agreement with the following statements. 
 
The current regulations promote effective protections for human subjects. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
The current regulations promote efficient review of protections for human subjects. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
40 
 
The current regulations are adequate and DO NOT need to be revised. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Before today, have you had an opportunity to familarize yourself with the advance notice of 
proposed rulemaking (ANPRM) introduced by DHHS? 
Yes 
No 
 
Institution Information 
How many currently active human subjects research studies does your IRB(s) oversee? 
Less than 500 studies 
501 - 1000 studies 
1001 - 1500 studies 
1501 - 2000 studies 
2001 - 2500 studies  
More than 2500 studies  
Not able to answer 
 
What types of human subjects research studies are reviewed by your IRB(s)? 
Biomedical only 
Social/Behavioral only 
Both biomedical and social/behavioral 
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What types of subject populations are included in the research reviewed by your IRB(s)? 
Adults only 
Children only 
Both adults and children 
 
Does your IRB review any clinical research studies (i.e., patient-oriented research, 
epidemiological and behavioral studies, or outcomes and health services research)? 
Yes 
No 
 
Is your institution classified as an academic medical center? 
Yes 
No 
 
Use of Central IRB(s) 
Has your institution ever used a central IRB? 
Yes 
No 
 
Central IRB Details – Have not used central IRB 
Please rate your level of agreement with the following statements. 
 
My institution does not participate in multi-site research so there is no need to go outside. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
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The institution's IRB(s) works efficiently so there is no need to go outside. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
The institution does not want to incur additional costs. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
The institution is concerned about the liability. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
The institution is concerned about the absence of local representation. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
The institution is unable to assess the quality/outcomes of the services used. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Is your institution planning on using a central IRB in the future? 
Yes 
No 
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On average, what is the total time for approval after submission to the central IRB? 
Less than 2 weeks 
15-21 days 
22-28 days 
4-6 weeks 
6 weeks - 3 months  
More than 3 months  
Not able to answer 
 
Central IRB details – Have used a central IRB 
Is your institution currently using a central IRB? 
Yes 
No 
 
Which protocols are or have been submitted to the central IRB? (Please check all that apply.) 
NIH funded Industry funded  
Foundation funded 
Institutional/Departmental funded 
Patient-oriented research 
Clinical trials 
Health services research  
Prevention Social/Behavioral 
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For studies sent to the central IRB, do you also require a local review? 
Yes 
No 
 
For local review of studies sent to central IRBs, what institutional committees need to approve 
protocols? (Please check all that apply.) 
Local IRB oversight review before or after central IRB review 
Pharmacy and Therapeutics 
Radiation Safety 
Oncology  
Gene Therapy  
Biosafety  
GCRC/CTSU  
Privacy 
Conflicts of Interest  
Scientific Review  
Other 
If Other, please specify: 
 
Do you maintain ongoing oversight (e.g., Adverse Event review, annual renewal, amendments, 
close out, investigator qualifications) of the research approved by the central IRB? 
Yes 
No 
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On average, what is the total time for approval after submission to the central IRB? 
Less than 2 weeks 
15-21 days 
22-28 days 
4-6 weeks 
6 weeks - 3 months  
More than 3 months  
Not able to answer 
 
On average, what is the total time for approval after submission to the local IRB? 
Less than 2 weeks 
15-21 days 
22-28 days 
4-6 weeks 
6 weeks - 3 months  
More than 3 months  
Not able to answer 
 
Please rate your level of agreement with the following statements. The use of a central IRB has 
shortened the time to approval. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
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We are pleased with the quality and level of the scientific review performed by the central IRB. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
We are pleased with the human subjects protection review performed by the central IRB. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
We are able to maintain excellent local oversight for studies approved by a central IRB. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Use of a central IRB has attracted industry sponsors. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Why did you choose to use a central IRB? (Please check all that apply.) 
Our IRB was shut down by OHRP 
Our local IRB is not currently functioning due to reorganization 
We couldn't keep up with the volume of protocols 
We feel there is less liability exposure using a central IRB  
We believe that a central IRB provides greater credibility  
Pressure from our investigators/researchers 
Other 
If Other, please specify: 
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Do you intend to continue to allow investigators to use a central IRB in the future? 
Yes 
No 
 
If you've used central IRBs in the past and then discontinued that use, why did you discontinue 
the use? 
 
 
Streamlining IRB Review of Multi-Site Studies 
The federal regulations currently do not require that a separate local IRB review be completed at 
each institution participating in a multi-site research study (with the exception of studies 
involving FDA-regulated medical devices). However, many insitutions still conduct a local IRB 
review. 
In the advance notice of proposed rulemaking, DHHS cites reports and studies which show that 
the practice of having numerous IRBs reviewing the same protocol results in significant delays 
and does not enhance the protections of human subjects.  DHHS argues that "relevant local 
contextual issues (e.g., investigator competence, site suitability) pertinent to most clinical studies 
can be addressed through mechanisms other than local IRB review" (p11). 
To remedy the delays and inefficient use of resources resulting from multiple IRB reviews of the 
same protocol, DHHS asks for public comments "on the feasibility, advantages, and 
disadvantages of mandating that all domestic sites in a multi-site study rely upon a single IRB as 
their IRB of record for that study" (p11). 
 
Please rate your level of agreement with the following statements. 
 
Multiple IRB reviews of multi-site studies significantly delays the initiation of research. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
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Local IRB review of a multi-site study adds to the protection of local human subjects. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
If single IRB review was mandated for all multi-site studies, I'm concerned about how the IRB of 
record would be selected. 
 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
I would agree with mandating single IRB review for multi-site studies as long as the IRB of 
record is held regulatorally accountable for their review. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
I would agree with mandating single IRB review for multi-site studies as long as the IRB of 
record is held legally liable for their review. 
 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
What additional concerns, if any, do you have with mandating single IRB review of mult-site 
research studies? 
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Ensuring Risk-Based Protections 
Another issue that DHHS addresses in the advance notice of proposed rulemaking is ensuring 
that the level of IRB review required adequately correlates to the level of risk of the research 
study.  DHHS cites criticisms that claim the current regulations do not match the level of review 
to the level of risk.  A specific example given is "surveys that are unlikely to lead to any harm to 
subjects nonetheless undergo review by a convened IRB" (p3). 
The following questions will introduce some of the proposed revisions to address these criticisms 
and ask for your opinion. 
 
Establishment of Mandatory Data Security and Information Protection Standards 
DHHS introduces the possibility of establishing mandatory data security and information 
protection standards in order to minimize the informational risks (or the risk of harm resulting 
from the unauthorized release of information about subjects) associated with research studies. 
The idea is that if researchers follow these mandatory standards then informational risks would 
be systematically minimized to the point where IRB review of these risks would not be 
necessary. 
If mandatory data security and information protections standards were implemented, indicate 
how comfortable you would be with the IRB no longer being responsible for review of a research 
study's plan for minimizing information risks. 
Neither Comfortable or 
Very Uncomfortable  Uncomfortable  Very Comfortable 
|-------------------------------------------------------------------------------------------| 
 
What additional concerns, if any, do you have with mandating data securtity standards thus 
eliminating the need for theIRB to assess informational risks? 
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Elimination of Continuing Review for Studies That Present No More Than Minimal Risk 
Another proposed revision would be to eliminate the requirement for continuing review of 
studies that present no more than minimal risk of harm to subjects. This would include all 
expedited studies as well as full review studies that have progressed to data analysis or long-term 
follow-up only. Included in this proposed revision is the caveat that continuing review could be 
required if the IRB reviewer determines that there is a justifiable reason why it would be 
appropriate for a specific study. 
 
Please rate your level of agreement with the following statements. 
 
I am comfortable with the IRB no longer conducting continuing review on most expedited 
studies. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
I am comfortable with the IRB no longer conducting continuing review on most full review 
studies that are in data analysis only. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
I am comfortable with the IRB no longer conducting continuing review on most full review 
studies that are in long-term follow-up only. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
What additional concerns, if any, would you have with the elimination of continuing review for 
minimal risk research studies/activities? 
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Changing "Exempt" to "Excused" 
DHHS is considering significant changes to the current concept of the exempt category. Given 
historical confusion over the "exempt" label and other proposed revisions (such as the mandatory 
data security standards discussed earlier) the current exempt categories would be translated to a 
new category called "excused." 
Studies in this new category would no longer be exempt from the regulations, but instead would 
be excused from IRB review prior to implementation. Investigator's could begin their research 
study after registering the study with the IRB rather than waiting for an IRB review to be 
completed before proceeding with research activities. DHHS proposes that instead, a 
tracking/audit system could be implemented effectively shifting resources from pre-
implementation review to post-implementation monitoring. 
In addition, DHHS is considering expanding the now "excused" categories to include more types 
of minimal risk studies. For example, DHHS recommends expanding exempt category 2 (45 
CFR 46.101[b][2]) to include all educational tests, surveys, focus groups and interviews with 
competent adults regardless of any identifying information being collected. 
 
Please rate your level of agreement with the following statements. 
 
Allowing  investigators  to  begin  research  activities  for  "excused"  studies  without  formal  
IRB  review  prior  to implementation is a good idea. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Shifting resources from pre-implementation review to post-implementation monitoring for 
"excused" studies would be a more efficient use of resources. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
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Shifting resources to post-implementation monitoring would result in more effective protections 
of human subjects than pre-implementation IRB review. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Including all survey-type research with competent adults into this new "excused" category, 
regardless of the type of data being collected, is a good idea. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
If a waiting period was required before an investigator could start an "excused" study, how long 
of a waiting period do you think would be appropriate? 
Less than 3 days 
4-6 days 
7-10 days 
11-14 days 
More than 14 days 
 
What additional concerns, if any, do you have with the proposed revisions to the regulations 
concerning "excused" studies? 
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Improving Informed Consent 
DHHS describes criticisms of the informed consent process ranging from the length and 
complexity of consent forms to the amount of time IRBs spend editing/revising them.  To 
address these concerns, DHHS is considering revising the regulations to ensure that consent 
forms: 
1. Include all the appropriate content necessary, 
2. Restrict inappropriate content, 
3. Are not too lengthy by limiting the acceptable length of sections, 
4. Include an appropriate order of information (e.g., specify what information should be at the 
beginning of the form), and 
5. Do not include excessive "boilerplate" language (e.g., language intended to protect 
institutional liability). 
Beyond revising the regulations regarding informed consent to be more specific, DHHS is also 
considering publishing standardized consent templates which would satisfy the new regulations. 
 
Please rate your level of agreement with the following statements. 
 
The current regulations need to be revised to provide more specific guidance on acceptable 
content in informed consent forms. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
Consent forms have become too lengthy and the regulations need to be revised to address this 
issue. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
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Consent forms today include too much information that is not pertinent to the subject (e.g., 
institutional "boilerplate" language) and the regulations need to be revised to address this issue. 
Neither Agree or 
Strongly Disagree  Disagree   Strongly Agree 
|-------------------------------------------------------------------------------------------| 
 
What additional concerns, if any, do you have with the proposed regulations regarding 
improvement to the informed consent process? 
 
Other Proposed Revisions 
The preceding survey included selected topics from the advance notice of proposed rulemaking 
which the current investigators believe will have the greatest impact on how IRBs function. 
Are there other topics in the advance notice of proposed rulemaking that you feel will have a 
greater impact (positive or negative) on the protection of human subjects?  If so, please explain: 
 
 
 
 
 
 
 
 
 
 
 
 
 
